Clinical trial
A Study to Evaluate the Efficacy of MEDI-528 on Late Asthmatic Response With…
NCT00394654 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00394654 |
|---|---|
| Title | A Study to Evaluate the Efficacy of MEDI-528 on Late Asthmatic Response With Atopic Asthma |
| Official title | A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy of MEDI-528, a Humanized Anti-Interleukin-9 Monoclonal Antibody, on Late Asthmatic Response Induced By Allergen Inhalation In Adults With Atopic Asthma |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Biological, Other |
| Interventions | MEDI-528 9 mg/kg, Placebo |
| Enrollment | 30 |
| Start date | Nov 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | Jan 1, 2008 |
| First posted | Nov 1, 2006 |
| Last update posted | Dec 11, 2013 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: